Pharmacoscopy-guided Clinical Standard-of-care in r/r AML

Recruiting now · Phase 2

Conditions studied: AML, Adult

In brief

With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.

Key facts

Study ID
NCT06138990
Run by
ETH Zurich
People needed
88
Starts
2024-09-02
Expected to finish
2026-06-30
Last updated by the study team
2025-05-16

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.